Apellis readies to compete with Soliris in PNH based on Phase III data

Apellis’ paroxysmal nocturnal hemoglobinuria candidate has beaten Soliris head-to-head on hemoglobin level improvement. Despite some ambiguity on how FDA will see the data, the company believes pegcetacoplan has a strong case for approval and could replace the Alexion drug as standard of care for PNH.

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) rose $8.54 (28%) to $38.73 Tuesday, gaining $546 million in market cap, after showing the C3 inhibitor met the primary endpoint in the Phase III PEGASUS trial to treat PNH...